Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $557
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Stephen Baxter has maintained an Overweight rating on Elevance Health (NYSE:ELV) but has lowered the price target from $561 to $557.

April 08, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wells Fargo maintains an Overweight rating on Elevance Health but lowers the price target from $561 to $557.
The adjustment in price target by Wells Fargo, while maintaining an Overweight rating, suggests a slight recalibration of expectations rather than a fundamental shift in the company's outlook. The minor reduction in the price target might reflect updated market conditions or minor concerns but doesn't change the overall positive stance. Investors might see this as a fine-tuning rather than a cause for concern.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100